2024 Q1 Form 10-Q Financial Statement

#000121390024057245 Filed on June 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1
Revenue $7.000K
YoY Change -46.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $988.0K
YoY Change -84.4%
% of Gross Profit
Research & Development $165.0K
YoY Change -46.6%
% of Gross Profit
Depreciation & Amortization $260.0K
YoY Change -72.01%
% of Gross Profit
Operating Expenses $1.186M
YoY Change -83.98%
Operating Profit -$1.179M
YoY Change -84.05%
Interest Expense $42.00K
YoY Change -81.33%
% of Operating Profit
Other Income/Expense, Net -$325.0K
YoY Change -115.62%
Pretax Income -$1.504M
YoY Change -80.31%
Income Tax
% Of Pretax Income
Net Earnings -$1.504M
YoY Change -80.31%
Net Earnings / Revenue -21485.71%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.24
COMMON SHARES
Basic Shares Outstanding 8.946M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.000K
YoY Change -99.86%
Cash & Equivalents $3.000K
Short-Term Investments
Other Short-Term Assets $104.0K
YoY Change -2.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $262.0K
YoY Change -95.83%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $2.621M
YoY Change 40.69%
Long-Term Investments
YoY Change
Other Assets $111.0K
YoY Change -93.58%
Total Long-Term Assets $2.732M
YoY Change -24.05%
TOTAL ASSETS
Total Short-Term Assets $262.0K
Total Long-Term Assets $2.732M
Total Assets $2.994M
YoY Change -69.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.988M
YoY Change 67.55%
Accrued Expenses $1.815M
YoY Change 49.75%
Deferred Revenue
YoY Change
Short-Term Debt $386.0K
YoY Change
Long-Term Debt Due $4.461M
YoY Change 32.37%
Total Short-Term Liabilities $17.07M
YoY Change 98.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $859.0K
YoY Change -34.92%
Total Long-Term Liabilities $859.0K
YoY Change -34.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.07M
Total Long-Term Liabilities $859.0K
Total Liabilities $17.93M
YoY Change 81.07%
SHAREHOLDERS EQUITY
Retained Earnings -$179.2M
YoY Change 15.72%
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$14.94M
YoY Change
Total Liabilities & Shareholders Equity $2.994M
YoY Change -69.67%

Cashflow Statement

Concept 2024 Q1
OPERATING ACTIVITIES
Net Income -$1.504M
YoY Change -80.31%
Depreciation, Depletion And Amortization $260.0K
YoY Change -72.01%
Cash From Operating Activities $1.716M
YoY Change -151.07%
INVESTING ACTIVITIES
Capital Expenditures $2.122M
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.122M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $371.0K
YoY Change
NET CHANGE
Cash From Operating Activities $1.716M
Cash From Investing Activities -$2.122M
Cash From Financing Activities $371.0K
Net Change In Cash -$35.00K
YoY Change -98.96%
FREE CASH FLOW
Cash From Operating Activities $1.716M
Capital Expenditures $2.122M
Free Cash Flow -$406.0K
YoY Change -87.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-39783
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
FOXO TECHNOLOGIES INC
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1050265
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
729 N. Washington Ave.
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55401
CY2024Q1 dei City Area Code
CityAreaCode
(612)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
562-9447
CY2024Q1 dei Security12b Title
Security12bTitle
Class A Common Stock, par value $0.0001
CY2024Q1 dei Trading Symbol
TradingSymbol
FOXO
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11280154 shares
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38000 usd
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
155000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
86000 usd
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
104000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
109000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
262000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
233000 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2621000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
378000 usd
CY2024Q1 us-gaap Other Assets
OtherAssets
111000 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
114000 usd
CY2024Q1 us-gaap Assets
Assets
2994000 usd
CY2023Q4 us-gaap Assets
Assets
725000 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4988000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4556000 usd
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
386000 usd
CY2024Q1 foxo Senior Paid In Kind Notes
SeniorPaidInKindNotes
4461000 usd
CY2023Q4 foxo Senior Paid In Kind Notes
SeniorPaidInKindNotes
4203000 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1815000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1696000 usd
CY2024Q1 foxo Accrued Settlement
AccruedSettlement
2260000 usd
CY2023Q4 foxo Accrued Settlement
AccruedSettlement
2260000 usd
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
42000 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
30000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
17072000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14336000 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
8000 usd
CY2024Q1 us-gaap Other Liabilities
OtherLiabilities
359000 usd
CY2023Q4 us-gaap Other Liabilities
OtherLiabilities
481000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
17931000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
14825000 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
164282000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162959000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179220000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-177060000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-14937000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-14100000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2994000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
725000 usd
CY2024Q1 us-gaap Revenues
Revenues
7000 usd
CY2023Q1 us-gaap Revenues
Revenues
13000 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
165000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
309000 usd
CY2024Q1 foxo Management Contingent Share Plans
ManagementContingentSharePlans
33000 usd
CY2023Q1 foxo Management Contingent Share Plans
ManagementContingentSharePlans
764000 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
988000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6332000 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
1186000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
7405000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1179000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7392000 usd
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8000 usd
CY2024Q1 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
301000 usd
CY2023Q1 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
225000 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-32000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-325000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-247000 usd
CY2024Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-1504000 usd
CY2023Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-7639000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1504000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7639000 usd
CY2024Q1 foxo Deemed Dividend From Trigger Of Down Round Provisions And Extension Of Assumed Warrants
DeemedDividendFromTriggerOfDownRoundProvisionsAndExtensionOfAssumedWarrants
656000 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2160000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7639000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6708000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7639000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
901000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-30000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-14100000 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2160000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
656000 usd
CY2024Q1 foxo Shares Issued Under Kr8 License Agreement Value
SharesIssuedUnderKR8LicenseAgreementValue
378000 usd
CY2024Q1 foxo Stock Issued During Period Value Share Issued Under Corporate Development And Advisory Agreement
StockIssuedDuringPeriodValueShareIssuedUnderCorporateDevelopmentAndAdvisoryAgreement
153000 usd
CY2024Q1 foxo Stock Issued During Period Value Warrants Issued For Finders Fees
StockIssuedDuringPeriodValueWarrantsIssuedForFindersFees
17000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
16000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
103000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-14937000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1504000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7639000 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
260000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
929000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
119000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
901000 usd
CY2024Q1 foxo Amortization Of Consulting Fees Paid In Common Stock
AmortizationOfConsultingFeesPaidInCommonStock
25000 usd
CY2023Q1 foxo Amortization Of Consulting Fees Paid In Common Stock
AmortizationOfConsultingFeesPaidInCommonStock
1725000 usd
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8000 usd
CY2024Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
258000 usd
CY2023Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
135000 usd
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
33000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
94000 usd
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
6000 usd
CY2023Q1 us-gaap Increase Decrease In Materials And Supplies
IncreaseDecreaseInMaterialsAndSupplies
-11000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-59000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-925000 usd
CY2024Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-5000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-7000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
983000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-489000 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1486000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
35000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1716000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3360000 usd
CY2024Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2122000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2122000 usd
CY2024Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
371000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
371000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-35000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3360000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5515000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2155000 usd
CY2024Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
378000 usd
CY2024Q1 foxo Warrants Issued For Finders Fee In Connection Promissory Notes
WarrantsIssuedForFindersFeeInConnectionPromissoryNotes
17000 usd
CY2024Q1 foxo Deemed Dividend From Trigger Of Down Round Provisions And Extension Of Assumed Warrant
DeemedDividendFromTriggerOfDownRoundProvisionsAndExtensionOfAssumedWarrant
656000 usd
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -45.35pt"><b><span style="text-decoration:underline">Note 1  DESCRIPTION OF BUSINESS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">FOXO Technologies Inc. (“FOXO” or the “Company”), formerly known as Delwinds Insurance Acquisition Corp. (“Delwinds”), a Delaware corporation, was originally formed in April 2020 as a publicly traded special purpose company for the purpose of effecting a merger, capital stock exchange, asset acquisition, reorganization, or similar business combination involving one or more businesses. FOXO is commercializing epigenetic biomarker technology to support groundbreaking scientific research and disruptive next-generation business initiatives. The Company applies automated machine learning and artificial intelligence (“AI”) technologies to discover epigenetic biomarkers of human health, wellness and aging. On October 29, 2023, the Company entered into a Letter Agreement with KR8 AI Inc., a Nevada corporation (“KR8” or the “Licensor”), to develop a Direct-to-Consumer app (iOS and Android) combining its AI Machine Learning technology to provide a commercial application of FOXO’s epigenetic biomarker technology as a subscription consumer engagement platform. In January 2024, the Letter Agreement was replaced by a definitive license agreement, which is more fully discussed in Note 6.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Segments</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company manages and classifies its business into two reportable business segments, FOXO Labs and FOXO Life. While the Company has decided to pause sales of new life insurance products, it still intends to continue to classify its business into the two reportable business segments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Business Combination</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 24, 2022, Delwinds entered into a definitive Agreement and Plan of Merger, dated as of February 24, 2022, as amended on April 26, 2022, July 6, 2022 and August 12, 2022 (the “Merger Agreement”), with FOXO Technologies Inc., now known as FOXO Technologies Operating Company (“FOXO Technologies Operating Company”), DWIN Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Delwinds (“Merger Sub”), and DIAC Sponsor LLC (the “Sponsor”), in its capacity as the representative of the stockholders of Delwinds from and after the closing (the “Closing”) of the transactions contemplated by the FOXO Transaction Agreement (collectively, the “Transaction” or the “Business Combination”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Business Combination was approved by Delwinds’ stockholders on September 14, 2022, and closed on September 15, 2022 (the “Closing Date”) whereby Merger Sub merged into FOXO Technologies Operating Company, with FOXO Technologies Operating Company surviving the merger as a wholly owned subsidiary of the Company (the “Combined Company”), and with FOXO Technologies Operating Company security holders becoming security holders of the Combined Company. Immediately upon the Closing, the name of Delwinds was changed to FOXO Technologies Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Closing, FOXO is a holding company whose wholly-owned subsidiary, FOXO Technologies Operating Company, conducts all of the core business operations. FOXO Technologies Operating Company maintains its two wholly-owned subsidiaries, FOXO Labs Inc. and FOXO Life, LLC. FOXO Labs maintains a wholly-owned subsidiary, Scientific Testing Partners, LLC, while FOXO Life Insurance Company was a wholly-owned subsidiary of FOXO Life, LLC. On February 3, 2023, the Company sold FOXO Life Insurance Company as more fully discussed in Note 9.</p>
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2160000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7639000 usd
CY2024Q1 foxo Working Capital Deficit
WorkingCapitalDeficit
16810000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-14937000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1716000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3360000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3000 usd
CY2024Q1 foxo Delinquent Amount Paid
DelinquentAmountPaid
65000000 usd
CY2024Q1 foxo Delinquent Amount Owes
DelinquentAmountOwes
146000000 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
256000 usd
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1339000 usd
CY2023Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 reverse stock split
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
471000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
214000 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2621000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
378000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
257000 usd
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
922000 usd
CY2023Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
2633000 usd
CY2022Q3 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
2918000 usd
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
540000 usd
CY2024Q1 foxo Paid In Kind Interest Rate
PaidInKindInterestRate
0.0115 pure
CY2024Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
20000000 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2000000 usd
CY2024Q1 foxo Pik Note Amendment
PIKNoteAmendment
1339000 usd
CY2024Q1 us-gaap Percentage Of Unamortized Film Costs
PercentageOfUnamortizedFilmCosts
0.10 pure
CY2024Q1 us-gaap Other Expenses
OtherExpenses
1596000 usd
CY2024Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
258000 usd
CY2023Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
135000 usd
CY2024Q1 foxo Future Purchase Notices Percentage
FuturePurchaseNoticesPercentage
0.10 pure
CY2023Q4 foxo Gross Proceeds Percentage
GrossProceedsPercentage
0.03 pure
CY2023Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q4 foxo Percentage Of Warrant Coverage
PercentageOfWarrantCoverage
1.10 pure
CY2024Q1 us-gaap Proceeds From Fees Received
ProceedsFromFeesReceived
371000 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
42000 usd
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
33000 usd
CY2024Q1 us-gaap Payments For Fees
PaymentsForFees
17000 usd
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
386000 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
196000 usd
CY2023Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
2018000 usd
CY2024Q1 foxo Development Fee
DevelopmentFee
2500000 usd
CY2024Q1 us-gaap Cost Maintenance
CostMaintenance
50000 usd
CY2024Q1 foxo Subscriber Revenuess Percentage
SubscriberRevenuessPercentage
0.15 pure
CY2024Q1 foxo Minimum Royalties
MinimumRoyalties
100000 usd
CY2024Q1 foxo Accrued Initial License And Development Fees
AccruedInitialLicenseAndDevelopmentFees
2623000 usd
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 foxo Outstanding Balance Percentage
OutstandingBalancePercentage
0.0999 pure
CY2024Q1 foxo Percentage Of Exercise Price
PercentageOfExercisePrice
1.10 pure
CY2024Q1 foxo Percentage Of Cash Fee
PercentageOfCashFee
0.03 pure
CY2024Q1 foxo Percentage Of Warrant Coverage For Equity Transaction
PercentageOfWarrantCoverageForEquityTransaction
0.07 pure
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
234000 usd
CY2023Q3 foxo Rights Shares Issued
RightsSharesIssued
511026 shares
CY2023Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
409000 shares
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
25672 shares
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
598877 shares
CY2024Q1 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2024-02-24
CY2024Q1 foxo Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exerciable
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExerciable
3315227 shares
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.34
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P1Y
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
25868 shares
CY2024Q1 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
15001 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
423700 shares
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1504000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7639000 usd
CY2024Q1 foxo Deemed Dividends Related To Assumed Warrants
DeemedDividendsRelatedToAssumedWarrants
-656000 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2160000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7639000 usd
CY2023 us-gaap Severance Costs1
SeveranceCosts1
1575000 usd
CY2023Q1 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments
462000 usd
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4540732 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1455770 shares
CY2023Q1 us-gaap Statutory Accounting Practices Statutory Capital And Surplus Required
StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired
5002000 usd
CY2023Q1 us-gaap Payments For Merger Related Costs
PaymentsForMergerRelatedCosts
200000 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
251000 usd
CY2024Q1 foxo Merger Consideration And Buyers Third Party Expenses Transaction Gain
MergerConsiderationAndBuyersThirdPartyExpensesTransactionGain
4751000 usd
CY2024Q1 us-gaap Revenues
Revenues
7000 usd
CY2023Q1 us-gaap Revenues
Revenues
13000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1504000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7639000 usd
CY2024Q1 foxo Amortization Of Consulting Fees
AmortizationOfConsultingFees
144000 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
260000 usd
CY2023Q1 foxo Consulting Agreement Expense
ConsultingAgreementExpense
2626000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
929000 usd
CY2024Q1 us-gaap Proceeds From Legal Settlements
ProceedsFromLegalSettlements
2260000 usd
CY2023 us-gaap Proceeds From Legal Settlements
ProceedsFromLegalSettlements
2260000 usd
CY2022Q4 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
6207000 usd
CY2024Q1 foxo Percentage Of Gross Proceeds
PercentageOfGrossProceeds
0.25 pure
CY2024Q1 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
300000 usd
CY2024Q1 us-gaap Accelerated Share Repurchases Settlement Payment Or Receipt
AcceleratedShareRepurchasesSettlementPaymentOrReceipt
50000 usd
CY2024Q1 foxo Revenues Received Percentage
RevenuesReceivedPercentage
0.15 pure
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
312500 shares
CY2024Q1 us-gaap Severance Costs1
SeveranceCosts1
1575000 usd
CY2024Q1 foxo Purchase Of Securities
PurchaseOfSecurities
840000 usd
CY2024Q1 foxo Purchases Of Securities Shares
PurchasesOfSecuritiesShares
1108755 shares
CY2024Q1 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
280000 usd
CY2024Q1 foxo Senior Notes Principal Amount
SeniorNotesPrincipalAmount
1120000 usd
CY2024Q1 foxo Accrued Interest Percentage
AccruedInterestPercentage
0.18 pure
CY2024Q1 foxo Percentage Of Prepayment
PercentageOfPrepayment
1 pure
CY2024Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
179000 usd
CY2023Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
13000 usd
CY2024Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-2069000 usd
CY2023Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-7738000 usd
CY2024Q1 us-gaap Dividends Common Stock
DividendsCommonStock
656000 usd
CY2024Q1 foxo Business Acquisitions Pro Forma Net Loss To Common Stockholders
BusinessAcquisitionsProFormaNetLossToCommonStockholders
-2725000 usd
CY2023Q1 foxo Business Acquisitions Pro Forma Net Loss To Common Stockholders
BusinessAcquisitionsProFormaNetLossToCommonStockholders
-7738000 usd
CY2024Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.23
CY2023Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-1.5
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 foxo Deemed Dividend From Trigger Of Down Round Provisions And Extension Of Assumed Warrants
DeemedDividendFromTriggerOfDownRoundProvisionsAndExtensionOfAssumedWarrants
usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2024Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
usd
CY2024Q1 us-gaap Increase Decrease In Materials And Supplies
IncreaseDecreaseInMaterialsAndSupplies
usd
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
usd
CY2023Q1 foxo Warrants Issued For Finders Fee In Connection Promissory Notes
WarrantsIssuedForFindersFeeInConnectionPromissoryNotes
usd
CY2023Q1 foxo Deemed Dividend From Trigger Of Down Round Provisions And Extension Of Assumed Warrant
DeemedDividendFromTriggerOfDownRoundProvisionsAndExtensionOfAssumedWarrant
usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2024Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q1 foxo Deemed Dividends Related To Assumed Warrants
DeemedDividendsRelatedToAssumedWarrants
usd
CY2023Q1 us-gaap Dividends Common Stock
DividendsCommonStock
usd
CY2024Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.23
CY2023Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-1.50
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001812360

Files In Submission

Name View Source Status
0001213900-24-057245-index-headers.html Edgar Link pending
0001213900-24-057245-index.html Edgar Link pending
0001213900-24-057245.txt Edgar Link pending
0001213900-24-057245-xbrl.zip Edgar Link pending
ea0208609-10q_foxotech.htm Edgar Link pending
ea020860901ex10-1_foxo.htm Edgar Link pending
ea020860901ex31-1_foxo.htm Edgar Link pending
ea020860901ex31-2_foxo.htm Edgar Link pending
ea020860901ex32-1_foxo.htm Edgar Link pending
ea020860901ex4-1_foxo.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
foxo-20240331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
foxo-20240331_pre.xml Edgar Link unprocessable
foxo-20240331_def.xml Edgar Link unprocessable
ea0208609-10q_foxotech_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
foxo-20240331_cal.xml Edgar Link unprocessable
foxo-20240331_lab.xml Edgar Link unprocessable